Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher G Bunick

Showing results (141-150 of 159) with videos related to

Pageof 16
Sort By:
The Journal of Dermatological Treatment|December 11, 2024
Real-world evidence on the benefits of optimal itch relief and skin clearance in atopic dermatitis management: a study from the TARGET-DERM AD registryJonathan I Silverberg, Brian M Calimlim, Ayman Grada, et al.
American Journal of Clinical Dermatology|May 5, 2026
Correction to: Real-World Evidence of Effectiveness and Safety of Abrocitinib, Baricitinib and Upadacitinib in Atopic Dermatitis: A Systematic Review and Meta-AnalysisAmalie Thorsti Møller Rønnstad, Daniel Isufi, Christopher G Bunick, et al.
The Journal of Clinical and Aesthetic Dermatology|December 19, 2025
Nemolizumab Demonstrates Marked Efficacy in Challenging Chronic Pruritus: A Real-world Multicenter Case SeriesDiego Ruiz Dasilva, Alondra Soto-González, Nicholas K Mollanazar, et al.
American Journal of Clinical Dermatology|February 8, 2026
Expert Recommendations for the Diagnosis and Management of Chronic Hand Eczema in the United StatesJonathan I Silverberg, David Cohen, Emma Guttman-Yassky, et al.
The Journal of Investigative Dermatology|May 26, 2016
Nonoverlapping Clinical and Mutational Patterns in Melanomas from the Female Genital Tract and Atypical Genital NeviOriol Yélamos, Emily A Merkel, Lauren Meldi Sholl, et al.
The British Journal of Dermatology|October 22, 2024
Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb/IV study (Level Up)Jonathan I Silverberg, Christopher G Bunick, H Chih-Ho Hong, et al.
The Journal of Dermatological Treatment|May 11, 2026
Long-term benefits of upadacitinib for Atopic Dermatitis: deep responses in patient-reported outcomes over 140 weeks from the Measure Up 1 and Measure Up 2 clinical trialsEric L Simpson, Vimal H Prajapati, Christopher G Bunick, et al.
Human Genomics|April 16, 2024
Altered skin microbiome, inflammation, and JAK/STAT signaling in Southeast Asian ichthyosis patientsMinh Ho, Huynh-Nga Nguyen, Minh Van Hoang, et al.
Dermatology and Therapy|June 26, 2025
Impact of Achieving Optimal Treatment Targets and Minimal Disease Activity on Health-Related Quality of Life and Satisfaction in Patients with Atopic DermatitisJonathan I Silverberg, Melinda Gooderham, Andreas Wollenberg, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 15, 2025
Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 yearsChristopher G Bunick, Alan D Irvine, Jonathan I Silverberg, et al.
Pageof 16

Showing results (141-150 of 159) with videos related to

Sort By:
Pageof 16
The Journal of Dermatological Treatment|December 11, 2024
Real-world evidence on the benefits of optimal itch relief and skin clearance in atopic dermatitis management: a study from the TARGET-DERM AD registryJonathan I Silverberg, Brian M Calimlim, Ayman Grada, et al.
American Journal of Clinical Dermatology|May 5, 2026
Correction to: Real-World Evidence of Effectiveness and Safety of Abrocitinib, Baricitinib and Upadacitinib in Atopic Dermatitis: A Systematic Review and Meta-AnalysisAmalie Thorsti Møller Rønnstad, Daniel Isufi, Christopher G Bunick, et al.
The Journal of Clinical and Aesthetic Dermatology|December 19, 2025
Nemolizumab Demonstrates Marked Efficacy in Challenging Chronic Pruritus: A Real-world Multicenter Case SeriesDiego Ruiz Dasilva, Alondra Soto-González, Nicholas K Mollanazar, et al.
American Journal of Clinical Dermatology|February 8, 2026
Expert Recommendations for the Diagnosis and Management of Chronic Hand Eczema in the United StatesJonathan I Silverberg, David Cohen, Emma Guttman-Yassky, et al.
The Journal of Investigative Dermatology|May 26, 2016
Nonoverlapping Clinical and Mutational Patterns in Melanomas from the Female Genital Tract and Atypical Genital NeviOriol Yélamos, Emily A Merkel, Lauren Meldi Sholl, et al.
The British Journal of Dermatology|October 22, 2024
Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb/IV study (Level Up)Jonathan I Silverberg, Christopher G Bunick, H Chih-Ho Hong, et al.
The Journal of Dermatological Treatment|May 11, 2026
Long-term benefits of upadacitinib for Atopic Dermatitis: deep responses in patient-reported outcomes over 140 weeks from the Measure Up 1 and Measure Up 2 clinical trialsEric L Simpson, Vimal H Prajapati, Christopher G Bunick, et al.
Human Genomics|April 16, 2024
Altered skin microbiome, inflammation, and JAK/STAT signaling in Southeast Asian ichthyosis patientsMinh Ho, Huynh-Nga Nguyen, Minh Van Hoang, et al.
Dermatology and Therapy|June 26, 2025
Impact of Achieving Optimal Treatment Targets and Minimal Disease Activity on Health-Related Quality of Life and Satisfaction in Patients with Atopic DermatitisJonathan I Silverberg, Melinda Gooderham, Andreas Wollenberg, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 15, 2025
Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 yearsChristopher G Bunick, Alan D Irvine, Jonathan I Silverberg, et al.
Pageof 16